Seven randomized controlled trials were included in this meta-analysis which investigated the use of oral bisphosphonates (etidronate, alendronate, or risendronate) in the prevention of hip fracture in the population suffering from neurological diseases, such as amylotrophic lateral sclerosis, stroke, or Parkinson's disease. Included studies were placebo controlled with the exception of one, which featured an active control group with alfacalcidol. The studies were conducted for a minimum of one year (up to two years). Pooled analyses indicated that intervention with etidronate, alendronate, or risendronate significantly reduced the relative risk of hip fracture compared to placebo or active control.